Which has preferable valuation & earnings, MRV or APH?

Aphria has higher revenue and earnings than Nuvo Pharmaceuticals. Nuvo Pharmaceuticals is trading at a lower price-to-earnings ratio than Aphria, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvo Pharmaceuticals C$8.72B 4.53 C$15.17M C$2.91 15.13 Aphria C$29.01B 10.23 C$4.93B C$0.43 60.19

Which has preferable earnings and valuation, VRX or APH?

Aphria has higher revenue and earnings than Valeant Pharmaceuticals International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valeant Pharmaceuticals International N/A N/A N/A N/A N/A Aphria C$29.01B 10.23 C$4.93B C$0.43 60.19

Is VRX or APH more profitable?

Company Net Margins Return on Equity Return on Assets Valeant Pharmaceuticals International N/A N/A N/A Aphria N/A N/A N/A

Which has stronger valuation and earnings, APH or APHA?

Aphria has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than Aphria, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aphria C$29.01B 10.23 C$4.93B C$0.43 60.19 Aphria C$611.06M 0.00 -C$637.39M -C$2.01 N/A

Is APH or APHA more profitable?

Company Net Margins Return on Equity Return on Assets Aphria N/A N/A N/A Aphria N/A N/A N/A

Do analysts recommend BHC or APH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Companies 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aphria 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, BHC or APH?

Aphria has higher revenue and earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Aphria, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch Health Companies C$10.85B 0.28 -C$125.65M -C$2.94 N/A Aphria C$29.01B 10.23 C$4.93B C$0.43 60.19

Do analysts rate APH or CRON?

Cronos Group has a consensus price target of C$4.92, indicating a potential upside of 6.65%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts clearly believe Cronos Group is more favorable than Aphria. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aphria 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cronos Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger valuation and earnings, APH or CRON?

Aphria has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Aphria, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aphria C$29.01B 10.23 C$4.93B C$0.43 60.19 Cronos Group C$179.09M 9.48 -C$32.78M C$0.19 24.26

Aphria (APH) Competitors

C$25.83 +0.39 (+1.53%)

As of 10/2/2026 03:58 PM Eastern

Compare

APH vs. MRV, VRX, APHA, BHC, and CRON

Should you buy Aphria stock or one of its competitors? Aphria's main competitors and comparable companies include Nuvo Pharmaceuticals (MRV), Valeant Pharmaceuticals International (VRX), Aphria (APHA), Bausch Health Companies (BHC), and Cronos Group (CRON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aphria compare to Nuvo Pharmaceuticals?

Nuvo Pharmaceuticals (TSE:MRV) and Aphria (TSE:APH) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Aphria shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aphria has higher revenue and earnings than Nuvo Pharmaceuticals. Nuvo Pharmaceuticals is trading at a lower price-to-earnings ratio than Aphria, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvo Pharmaceuticals	C$8.72B	4.53	C$15.17M	C$2.91	15.13
Aphria	C$29.01B	10.23	C$4.93B	C$0.43	60.19

Nuvo Pharmaceuticals has a beta of 0.917796, meaning that its share price is 8% less volatile than the broader market. Comparatively, Aphria has a beta of 3.455044, meaning that its share price is 246% more volatile than the broader market.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Aphria's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Aphria's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvo Pharmaceuticals	20.95%	1,180.47%	5.85%
Aphria	N/A	N/A	N/A

In the previous week, Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Aphria'saverage media sentiment score.

Company	Overall Sentiment
Nuvo Pharmaceuticals	Neutral
Aphria	Neutral

Summary

Nuvo Pharmaceuticals beats Aphria on 6 of the 11 factors compared between the two stocks.

How does Aphria compare to Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International (TSE:VRX) and Aphria (TSE:APH) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

0.0% of Aphria shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aphria has higher revenue and earnings than Valeant Pharmaceuticals International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valeant Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
Aphria	C$29.01B	10.23	C$4.93B	C$0.43	60.19

Company	Net Margins	Return on Equity	Return on Assets
Valeant Pharmaceuticals International	N/A	N/A	N/A
Aphria	N/A	N/A	N/A

In the previous week, Valeant Pharmaceuticals International's average media sentiment score of 0.00 equaled Aphria'saverage media sentiment score.

Company	Overall Sentiment
Valeant Pharmaceuticals International	Neutral
Aphria	Neutral

Summary

Aphria beats Valeant Pharmaceuticals International on 2 of the 2 factors compared between the two stocks.

How does Aphria compare to Aphria?

Aphria (TSE:APH) and Aphria (TSE:APHA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, Aphria's average media sentiment score of 0.00 equaled Aphria'saverage media sentiment score.

Company	Overall Sentiment
Aphria	Neutral
Aphria	Neutral

Aphria has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than Aphria, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aphria	C$29.01B	10.23	C$4.93B	C$0.43	60.19
Aphria	C$611.06M	0.00	-C$637.39M	-C$2.01	N/A

0.0% of Aphria shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Aphria	N/A	N/A	N/A
Aphria	N/A	N/A	N/A

Summary

Aphria beats Aphria on 5 of the 5 factors compared between the two stocks.

How does Aphria compare to Bausch Health Companies?

Bausch Health Companies (TSE:BHC) and Aphria (TSE:APH) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Aphria has higher revenue and earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Aphria, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Companies	C$10.85B	0.28	-C$125.65M	-C$2.94	N/A
Aphria	C$29.01B	10.23	C$4.93B	C$0.43	60.19

In the previous week, Bausch Health Companies had 4 more articles in the media than Aphria. MarketBeat recorded 4 mentions for Bausch Health Companies and 0 mentions for Aphria. Bausch Health Companies' average media sentiment score of 0.72 beat Aphria's score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the media.

Company	Overall Sentiment
Bausch Health Companies	Positive
Aphria	Neutral

Bausch Health Companies has a beta of 0.707626, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Aphria has a beta of 3.455044, suggesting that its share price is 246% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Companies	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aphria	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aphria has a net margin of 0.00% compared to Bausch Health Companies' net margin of -12.02%. Bausch Health Companies' return on equity of 87.57% beat Aphria's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Companies	-12.02%	87.57%	4.16%
Aphria	N/A	N/A	N/A

9.7% of Bausch Health Companies shares are held by institutional investors. Comparatively, 0.0% of Aphria shares are held by institutional investors. 11.3% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Bausch Health Companies and Aphria tied by winning 7 of the 14 factors compared between the two stocks.

How does Aphria compare to Cronos Group?

Aphria (TSE:APH) and Cronos Group (TSE:CRON) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Aphria has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Aphria, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aphria	C$29.01B	10.23	C$4.93B	C$0.43	60.19
Cronos Group	C$179.09M	9.48	-C$32.78M	C$0.19	24.26

Cronos Group has a net margin of 38.95% compared to Aphria's net margin of 0.00%. Cronos Group's return on equity of 6.46% beat Aphria's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aphria	N/A	N/A	N/A
Cronos Group	38.95%	6.46%	-3.73%

Aphria has a beta of 3.455044, suggesting that its stock price is 246% more volatile than the broader market. Comparatively, Cronos Group has a beta of 1.29991, suggesting that its stock price is 30% more volatile than the broader market.

In the previous week, Cronos Group had 4 more articles in the media than Aphria. MarketBeat recorded 4 mentions for Cronos Group and 0 mentions for Aphria. Aphria's average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company	Overall Sentiment
Aphria	Neutral
Cronos Group	Neutral

0.0% of Aphria shares are held by institutional investors. Comparatively, 4.3% of Cronos Group shares are held by institutional investors. 46.4% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cronos Group has a consensus price target of C$4.92, indicating a potential upside of 6.65%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts clearly believe Cronos Group is more favorable than Aphria.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aphria	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Cronos Group beats Aphria on 8 of the 15 factors compared between the two stocks.

Get Aphria News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APH vs. The Competition

Export

Metric	Aphria	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$296.83B	C$12.27B	C$7.14B	C$12.53B
Dividend Yield	0.22%	2.64%	2.53%	6.31%
P/E Ratio	60.19	794.62	273.77	39.33
Price / Sales	10.23	757.06	619.77	9.16
Price / Cash	N/A	82.26	77.60	82.29
Price / Book	N/A	10.46	10.92	4.61
Net Income	N/A	C$2.83B	C$3.50B	C$299.09M
7 Day Performance	3.65%	-1.54%	-2.07%	-1.15%
1 Month Performance	5.99%	-5.66%	-6.21%	-2.87%
1 Year Performance	N/A	-4.69%	7.45%	16.48%

Aphria Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APH Aphria	N/A	C$25.83 +1.5%	N/A	N/A	C$296.83B	C$29.01B	60.19	170,000
MRV Nuvo Pharmaceuticals	N/A	C$42.71 +2.0%	N/A	N/A	C$38.33B	C$8.72B	14.68	7,480
VRX Valeant Pharmaceuticals International	N/A	N/A	N/A	N/A	C$10.76B	N/A	N/A	N/A
APHA Aphria	N/A	N/A	N/A	N/A	C$5.24B	C$611.06M	N/A	1,200
BHC Bausch Health Companies	0.9021 of 5 stars	C$8.03 +0.8%	N/A	-9.7%	C$3.00B	C$10.85B	N/A	20,300	News Coverage Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:APH) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aphria (APH) Competitors

APH vs. MRV, VRX, APHA, BHC, and CRON

How does Aphria compare to Nuvo Pharmaceuticals?

Summary

How does Aphria compare to Valeant Pharmaceuticals International?

Summary

How does Aphria compare to Aphria?

Summary

How does Aphria compare to Bausch Health Companies?

Summary

How does Aphria compare to Cronos Group?

Summary

Media Sentiment Over Time

APH vs. The Competition

Aphria Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aphria (APH) Competitors

APH vs. MRV, VRX, APHA, BHC, and CRON

How does Aphria compare to Nuvo Pharmaceuticals?

Do institutionals & insiders believe in MRV or APH?

Which has preferable valuation & earnings, MRV or APH?

Which has more risk and volatility, MRV or APH?

Is MRV or APH more profitable?

Does the media refer more to MRV or APH?

Summary

How does Aphria compare to Valeant Pharmaceuticals International?

Do insiders and institutionals believe in VRX or APH?

Which has preferable earnings and valuation, VRX or APH?

Is VRX or APH more profitable?

Does the media refer more to VRX or APH?

Summary

How does Aphria compare to Aphria?

Does the media favor APH or APHA?

Which has stronger valuation and earnings, APH or APHA?

Do institutionals and insiders believe in APH or APHA?

Is APH or APHA more profitable?

Summary

How does Aphria compare to Bausch Health Companies?

Which has higher valuation & earnings, BHC or APH?

Does the media prefer BHC or APH?

Which has more volatility & risk, BHC or APH?

Do analysts recommend BHC or APH?

Is BHC or APH more profitable?

Do insiders and institutionals hold more shares of BHC or APH?

Summary

How does Aphria compare to Cronos Group?

Which has stronger valuation and earnings, APH or CRON?

Is APH or CRON more profitable?

Which has more volatility and risk, APH or CRON?

Does the media favor APH or CRON?

Do institutionals & insiders have more ownership in APH or CRON?

Do analysts rate APH or CRON?

Summary

Media Sentiment Over Time

APH vs. The Competition

Aphria Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools